Revolution's Pancreatic Cancer Drug Doubles Survival and Improves Quality of Life

An international trial presented at the American Society of Clinical Oncology congress revealed that Revolution's new drug, daraxonrasib, significantly increases survival rates and boosts quality of life for patients with metastatic pancreatic tumors, with France also rolling out a prevention program.